Impact assessment

Branded medicines supplied to the NHS

This publication was published under the 2010 to 2015 Conservative and Liberal Democrat coalition government

Information on the Health Service Branded Medicines (Control of Prices and Supply of Information) (No. 2) Regulations 2008.

Documents

Impact assessment number 6089

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (eg a screen reader) and need a version of this document in a more accessible format, please email publications@dh.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Excel list of products not exempt under section 4 of the regulations

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (eg a screen reader) and need a version of this document in a more accessible format, please email publications@dh.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Detail

The Health Service Branded Medicines (Control of Prices and Supply of Information) (No.2) Regulations 2008 (“the Prices Regulations”) is a statutory scheme that applies to all companies supplying branded medicines to the NHS, which have not joined the Pharmaceutical Price Regulation Scheme (PPRS).

The PPRS regulates prices of branded prescription medicines by regulating the profits that manufacturers are allowed to make on their sales to the NHS.

The Secretary of State for Health has made an amendment to these regulations which came into force on 1 January 2013.

The Health Service Branded Medicines (Control of Prices and Supply of Information) Amendment Regulations 2012 and explanatory memorandum.

On 19 May 2014 the department published a statement on over the counter medicines: Health Service Medicines (Control of Prices and Supply of Information) (Amendment) Regulations 2013.